NorthWest Biotherapeutics Inc (NWBO): Larppis Re: ATLnsider post# 539288...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	112
Posts	8406
Boards Moderated	0
Alias Born	02/27/2016

ae kusterer

Re: None

Sunday, 11/27/2022 10:05:28 AM

Sunday, November 27, 2022 10:05:28 AM

Larppis

Re: ATLnsider post# 539288

Sunday, November 27, 2022 12:41:29 AM

Post#
539289
of 539352
There are actually two different sites to read about the SPORE projects. On the other one they specifically mention Merck and Pembrolizumab (Keytruda), on the other one they do not.

This one has the mention:
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm

This one does not:
https://cancer.ucla.edu/research/ucla-brain-spore/research-projects
ATLnsider

Re: biosectinvestor post# 539285

Sunday, November 27, 2022 12:31:54 AM

Post#
539288
of 539351
Also, I don’t believe the UCLA Spore project actually specified Keytruda would be used in the combo trial. I only see it saying: PD-1 mab

As you may know, “mab” is the suffix ending for all PD-1 inhibitors, and it includes BMY’s product Opdivo (nivolumab).

Here is the UCLA Spore project info: